Core Viewpoint - HEALWELL AI Inc. is clarifying its forward-looking information regarding its strategic divestments and financial performance, emphasizing its transition to a pure-play digital SaaS and AI business focused on health systems and large enterprises globally [1][3]. Financial Performance - The company reported quarterly revenue from continuing operations of $30.4 million in Q3-2025, which annualizes to an approximate revenue run-rate of $120 million, representing a 354% increase compared to revenue of $6.7 million in Q3-2024 [11]. - HEALWELL achieved a positive Adjusted EBITDA of $0.7 million in Q3-2025, compared to an Adjusted EBITDA loss of $2.8 million in Q3-2024, marking the second consecutive quarter of positive Adjusted EBITDA [11]. Strategic Transactions - The November 3rd Release announced the completion of three strategic transactions, including the sale of two non-core businesses and the contribution of two more to a clinical research joint venture, allowing HEALWELL to focus on its core digital SaaS and AI business [3][4]. AI Capabilities and Market Positioning - HEALWELL's AI solutions have received external recognition and validation, particularly through its DARWEN™ AI platform, which specializes in extracting real-world evidence from unstructured clinical data [7][8]. - The company has been recognized for its contributions to healthcare accessibility and preventative care, winning the Prix Galien USA 2024 for Best Digital Health Startup [8]. Research Validation - HEALWELL's AI technologies have been validated through various peer-reviewed studies, demonstrating their effectiveness in automating processes and improving clinical outcomes [12].